Regulation of IL-1β–induced NF-κB by hydroxylases links key hypoxic and inflammatory signaling pathways
Hypoxia is a prominent feature of chronically inflamed tissues. Oxygen-sensing hydroxylases control transcriptional adaptation to hypoxia through the regulation of hypoxia-inducible factor (HIF) and nuclear factor κB (NF-κB), both of which can regulate the inflammatory response. Furthermore, pharmac...
Saved in:
Published in | Proceedings of the National Academy of Sciences - PNAS Vol. 110; no. 46; pp. 18490 - 18495 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
National Academy of Sciences
12.11.2013
NATIONAL ACADEMY OF SCIENCES National Acad Sciences |
Series | From the Cover |
Subjects | |
Online Access | Get full text |
ISSN | 0027-8424 1091-6490 1091-6490 |
DOI | 10.1073/pnas.1309718110 |
Cover
Summary: | Hypoxia is a prominent feature of chronically inflamed tissues. Oxygen-sensing hydroxylases control transcriptional adaptation to hypoxia through the regulation of hypoxia-inducible factor (HIF) and nuclear factor κB (NF-κB), both of which can regulate the inflammatory response. Furthermore, pharmacologic hydroxylase inhibitors reduce inflammation in multiple animal models. However, the underlying mechanism(s) linking hydroxylase activity to inflammatory signaling remains unclear. IL-1β, a major proinflammatory cytokine that regulates NF-κB, is associated with multiple inflammatory pathologies. We demonstrate that a combination of prolyl hydroxylase 1 and factor inhibiting HIF hydroxylase isoforms regulates IL-1β–induced NF-κB at the level of (or downstream of) the tumor necrosis factor receptor-associated factor 6 complex. Multiple proteins of the distal IL-1β–signaling pathway are subject to hydroxylation and form complexes with either prolyl hydroxylase 1 or factor inhibiting HIF. Thus, we hypothesize that hydroxylases regulate IL-1β signaling and subsequent inflammatory gene expression. Furthermore, hydroxylase inhibition represents a unique approach to the inhibition of IL-1β–dependent inflammatory signaling. |
---|---|
Bibliography: | http://dx.doi.org/10.1073/pnas.1309718110 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Edited by Michail V. Sitkovsky, Northeastern University, Boston, MA, and accepted by the Editorial Board September 18, 2013 (received for review May 22, 2013) Author contributions: C.C.S., P.G.F., E.P.C., and C.T.T. designed research; C.C.S., M.A.S.C., M.M.T., E.H., J.R., A.v.K., A.C., and E.P.C. performed research; C.C.S., M.A.C., M.M.T., J.R., A.v.K., P.C., U.B., A.C., E.P.C., and C.T.T. analyzed data; and C.C.S. and C.T.T. wrote the paper. 1E.P.C. and C.T.T. contributed equally to this work. |
ISSN: | 0027-8424 1091-6490 1091-6490 |
DOI: | 10.1073/pnas.1309718110 |